A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.
Shipo WuGongxun ZhongJun ZhangLei ShuaiZhe ZhangZhiyuan WenBusen WangZhenghao ZhaoXiaohong SongYi ChenRenqiang LiuLing FuJinlong ZhangQiang GuoChong WangYilong YangTing FangPeng LvJinliang WangJunjie XuJianmin LiChangming YuLihua HouZhi-Gao BuWei ChenPublished in: Nature communications (2020)
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- public health
- respiratory tract
- wild type
- endothelial cells
- clinical trial
- infectious diseases
- induced pluripotent stem cells
- healthcare
- emergency department
- randomized controlled trial
- gene therapy
- type diabetes
- metabolic syndrome
- protein protein
- drug induced
- small molecule
- high fat diet induced
- phase ii